New combo therapy aims to tame leukemia in older patients
NCT ID NCT01371630
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests a drug called inotuzumab ozogamicin, which delivers a toxin directly to leukemia cells, combined with low-intensity chemotherapy. It includes about 276 adults with acute lymphoblastic leukemia (ALL), especially those over 60 or unfit for standard treatment. The goal is to find the best dose and see if the combo improves survival and remission rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inotuzumab ozogamicin (a targeted antibody-drug combo) plus chemotherapy drugs
What this could lead to
If successful, this could offer a more effective and less harsh treatment option for older or frail patients with acute lymphoblastic leukemia.
What could go wrong
This is an early-phase trial combining multiple drugs, so side effects and safety are still being evaluated. It may not work for all patients or could cause serious toxicities.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.